Hot-melt drug release stent

Abstract

The invention provides a hot-melt drug release stent, and relates to the technical field of medical instruments. The hot melting coating is arranged on the bracket body; the medicine layer is arranged on the hot melting coating; the wrapping layer is arranged on the hot melting coating and wraps the medicine layer; a heating assembly is arranged in a cavity formed by the stent body, the heating assembly heats the stent body, and the resistance block transfers heat to decompose the hot melting coating so as to release medicine. According to the drug stent, the hot melting coating, the drug layer and the wrapping layer are arranged, the heating assembly is used for heating the resistance block, heat of the resistance block is conducted to the hot melting coating to promote decomposition of the hot melting coating, then the drug layer is released and makes direct contact with the lesion position, proliferation of cells at the lesion position is inhibited, and after the function is completed, the stent body of the drug stent can be withdrawn, so that the drug stent is convenient to use. And the implant is not left in vivo like a permanent implant for a long time, so that the risk of long-term foreign body reaction and complication is reduced.

Description

Technical Field

[0001] The invention belongs to the technical field of medical devices, and in particular relates to a hot-melt drug-releasing stent. Background Art

[0002] Vascular stenosis is one of the important causes of myocardial infarction, stroke and other diseases, and poses a huge threat to human life and health. Vascular stenosis is often accompanied by the formation of atherosclerotic plaques. As atherosclerotic plaques gradually grow larger, the lumen of the blood vessels becomes narrower, reducing blood flow, which makes it difficult for organs behind the affected area to get sufficient blood supply, resulting in necrosis.

[0003] At present, in order to treat vascular stenosis, interventional treatment is generally used to reopen blocked blood vessels. Traditionally, the treatment of vascular stenosis mainly relies on stent implantation, in which a drug layer is set on the stent to treat the lesion, that is, a metal stent is implanted into the narrowed blood vessel through a catheter to open the blood vessel cavity and restore blood flow. The drug layer is attached to the lesion to treat the lesion and inhibit restenosis. Stenotic blood vessels generally complete the repair and remodeling of the blood vessels within 6 to 12 months. However, as a support device, vascular stents remain in the blood vessels for a long time, and gradually endothelialize during the process of vascular expansion and remodeling. Patients usually need to take antiplatelet drugs for a long time to prevent the formation of blood clots, but there is still poor endothelialization, leading to inflammation and stent thrombosis.

[0004] Therefore, it is necessary to provide an improved technical solution to address the above-mentioned deficiencies in the prior art. Summary of the invention

[0005] The purpose of the present invention is to provide a drug-releasing stent that inhibits hot-melt release, which releases drugs by melting the hot-melt coating through a heating component and recovers the drugs after the release is completed, so as to solve the problem that traditional balloon stents need to remain in blood vessels.

[0006] In order to achieve the above object, the present invention provides the following technical solutions:

[0007] A hot-melt drug-releasing stent, comprising a stent body;

[0008] A hot-melt coating is disposed on the support body;

[0009] a drug layer, disposed on the hot-melt coating;

[0010] A coating layer, disposed on the hot-melt coating layer and covering the drug layer;

[0011] The stent body is connected to a heating assembly, the heating assembly includes an input line connected to the proximal end of the stent body, the part of the input line located outside the body is connected to a power source, and the distal end of the stent body is connected to an output line;

[0012] The support body is provided with a resistance block located at the hot-melt coating.

[0013] When the resistor block is energized, it generates heat and heats the hot-melt coating, causing the hot-melt coating to decompose and release the drug.

[0014] Preferably, the coating layer is a PLG coating.

[0015] Preferably, the drug layer is arranged to protrude in a direction away from the stent body.

[0016] Preferably, the resistor block is protrudingly arranged and embedded in the hot-melt coating.

[0017] Preferably, a separation layer is provided on the stent body and is located between the resistance block and the hot-melt coating. The separation layer is a thin film with good biocompatibility.

[0018] Preferably, it further comprises a sheath tube with two cavities which are not connected to each other, the input line and the output line are respectively located in one of the cavities, and the sheath tube is connected to the proximal end of the stent body.

[0019] Preferably, the hot melt coating is made of a thermoplastic resin, and the thermoplastic resin includes but is not limited to polybutadiene.

[0020] Preferably, the heating temperature of the bracket body is 40°C-41°C.

[0021] Preferably, the drug layer is any one or more of rapamycin, its structural derivatives, paclitaxel, and its structural derivatives.

[0022] Preferably, a plurality of developing points are arranged on the support body, and a developing point is also arranged at the connection between the support body and the hot-melt coating.

[0023] Beneficial effects:

[0024] (1) The present invention provides a hot-melt coating, a drug layer and a coating layer bonded to the stent body. After the stent body expands, it adheres to the blood vessel. Then, the hot-melt coating is decomposed by a heating component, thereby releasing the drug to treat the lesion. After the drug is released, it can be recovered, and the stent body is not left in the body, thereby reducing the risk of long-term foreign body reaction and complications.

[0025] (2) The present invention provides a coating layer, which is a PLG coating, so that the coating layer is biodegradable and can be degraded into lactic acid and glycolic acid with less impact on the physiological environment after a period of time in the blood vessel, thereby reducing the risk of thrombosis at the coating layer;

[0026] (3) The present invention provides a resistor block so that heat can be more concentrated on the resistor block after power is turned on, which facilitates heat conduction to the hot-melt coating, allowing the hot-melt coating to decompose stably and the drug to be released. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] The drawings constituting a part of the present application are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. Among them:

[0028] Figure 1 This is a schematic diagram of the overall structure of the hot-melt drug-releasing stent in a compressed state according to an embodiment of the present invention;

[0029] Figure 2 for Figure 1 A schematic diagram for showing the distal structure of the hot-melt drug-releasing stent;

[0030] Figure 3 Schematic diagram of the side view structure of the sheath tube;

[0031] Figure 4 It is a schematic diagram of the overall structure of the hot-melt drug-releasing stent in an expanded state according to an embodiment of the present invention;

[0032] Figure 5 It is a schematic diagram of the structure of the hot-melt drug-releasing stent located at the lesion in an embodiment of the present invention. At this time, the stent body is in the process of expansion.

[0033] In the figure: 1, stent body; 11, separation layer; 2, hot-melt coating; 3, drug layer; 4, coating layer; 51, input line; 52, output line; 53, resistor block; 6, sheath; 7, development point. DETAILED DESCRIPTION

[0034] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. All other embodiments obtained by ordinary technicians in this field based on the embodiments of the present invention belong to the scope of protection of the present invention.

[0035] In the description of the present invention, it should be understood that descriptions involving orientations, such as up, down, front, back, left, right, etc., and orientations or positional relationships indicated are based on the orientations or positional relationships shown in the accompanying drawings, and are only for the convenience of describing the present invention and simplifying the description, and do not indicate or imply that the device or element referred to must have a specific orientation, be constructed and operated in a specific orientation, and therefore should not be understood as a limitation on the present invention.

[0036] In the description of the present invention, "several" means one or more, "more" means more than two, "greater than", "less than", "exceed" etc. are understood as not including the number itself, and "above", "below", "within" etc. are understood as including the number itself. If there is a description of "first" or "second", it is only used for the purpose of distinguishing the technical features, and cannot be understood as indicating or implying the relative importance or implicitly indicating the number of the indicated technical features or implicitly indicating the order of the indicated technical features.

[0037] In addition, the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Thus, the features defined as "first" and "second" may explicitly or implicitly include one or more features.

[0038] In the description of the present invention, it should be noted that, unless otherwise clearly stipulated and limited, the term "connection" should be understood in a broad sense. For example, it can be a fixed connection or a movable connection, a detachable connection or a non-detachable connection, or an integral connection; it can be a mechanical connection, an electrical connection, or mutual communication; it can be a direct connection, or an indirect connection through an intermediate medium, and it can be internal connection between two elements, indirect connection, or an interactive relationship between two elements.

[0039] In the description of the present invention, the "distal end" refers to the end farther from the doctor during surgery, and the "proximal end" refers to the end closer to the doctor during surgery.

[0040] In the description of the present invention, "before use" refers to the state of the hot-melt drug-releasing stent before use, before entering the human body, or before contacting with body fluids such as blood and tissue fluid in the human body, and "during use" refers to the state of the hot-melt drug-releasing stent after entering the human body or contacting with body fluids such as blood and tissue fluid in the human body.

[0041] In the description of the present invention, the "gathered state" refers to the state in which the "branch conduits" are attached to each other within a partial length range or within the entire length range.

[0042] In the description of the present invention, "in vivo environment" refers to the environment below the epidermis of the skin where body fluids exist, such as the dermis and subcutaneous tissue, or the inside of blood vessels and organs.

[0043] The present invention will be described in detail below in conjunction with embodiments. It should be noted that the embodiments and features in the embodiments of the present invention can be combined with each other without conflict.

[0044] The present invention aims at the problem that the vascular stent in the prior art is used as a supporting device and stays in the blood vessel for a long time. Patients usually need to take antiplatelet drugs for a long time to prevent the formation of blood clots, but there is still a problem of poor endothelialization effect, leading to inflammation, stent thrombosis and other diseases.

[0045] The present invention discloses a hot melt drug release stent, referring to Figure 1 and Figure 2 , comprising a bracket body 1;

[0046] A hot-melt coating 2 is provided on the bracket body 1;

[0047] A drug layer 3 is provided on the hot-melt coating 2;

[0048] A coating layer 4 is provided on the hot-melt coating layer 2 and covers the drug layer 3;

[0049] A heating component is disposed in the cavity formed by the stent body 1 , and the heating component heats the stent body 1 after the stent body 1 expands. The stent body 1 transfers heat to melt the hot-melt coating 2 to release the drug.

[0050] Reference Figure 1 , Figure 2 and Figure 3 The stent body 1 is a mesh-shaped stent made of alloy wire with memory function. Preferably, nickel-titanium alloy wire is selected. The nickel-titanium alloy wire has shape memory function and can automatically return to its original shape after release to meet the needs of radial expansion. The stent body 1 can be woven from nickel-titanium alloy wire or laser engraved from nickel-titanium alloy. Nickel-titanium alloy also has a conductive function and can generate heat after power is turned on.

[0051] The hot melt coating 2 is attached to the outer surface of the stent body 1 by bonding. The hot melt coating 2 is a film made of polybutadiene, which has certain elasticity and flexibility. During the expansion of the stent body 1, it can expand with the stent body 1 and maintain a bonding relationship with the stent body 1, so that the doctor can better control the position of the drug layer 3. At the same time, the tear resistance of the hot melt coating 2 is improved. It should be noted that polybutadiene will accelerate decomposition when heated to 40°C, allowing the drug in the drug layer 3 to be released.

[0052] The hot-melt coating 2 is disposed between the stent body 1 and the drug layer 3 , and only covers the drug layer 3 .

[0053] Preferably, the drug layer 3 is an anti-proliferative drug, such as one or more of paclitaxel and rapamycin. One end of the drug layer 3 close to the hot-melt coating 2 is adhered to the hot-melt coating 2. After the hot-melt coating 2 is decomposed, the drug in the drug layer 3 is released and adheres to the vascular lesion, thereby inhibiting the proliferation of cells in the lesion.

[0054] Furthermore, the coating layer 4 is a biodegradable film bonded to the hot-melt coating 2, and the coating layer 4 and the hot-melt coating 2 form a cavity for accommodating the drug, which is used to wrap the drug layer 3 to prevent the loss of the drug layer 3 during transportation. The coating layer 4 is preferably a PLG coating. In the in vivo environment, the PLG coating will gradually degrade into lactic acid and glycolic acid, which are small molecule products that are common substances in the human body's metabolic process and can be further decomposed and excreted from the body through metabolic pathways.

[0055] Reference Figure 1 , Figure 2 and Figure 3 Furthermore, the heating component includes an input line 51 connected to the proximal end of the stent body 1, the part of the input line 51 outside the body is connected to a power source, and the distal end of the stent body 1 is connected to an output line 52. The power source energizes the stent body 1 through the loop formed by the input line 51 and the output line 52, so that the stent body 1 is heated. The stent body 1 has a certain thermal conductivity. A resistor block 53 located at the hot-melt coating 2 is welded on the stent body 1. The resistor block 53 is made of a material with a high resistivity, preferably copper. The resistor block 53 is protruding and embedded in the hot-melt coating 2 to increase the contact area. After conduction, the copper has a high resistance, which allows the resistor block 53 to accumulate heat and conduct the heat to the hot-melt coating 2, thereby causing the hot-melt coating 2 to decompose and complete the release of the drug.

[0056] Reference Figures 1 to 4 A separation layer 11 located between the resistor block 53 and the hot-melt coating 2 is welded or bonded to the stent body 1. The separation layer 11 is a thin film with good biocompatibility, such as a nickel-titanium alloy coating, a PTFE film or a PU film. The thickness of the separation layer 11 is not more than 0.1 mm. A thinner separation layer 11 can reduce the impact on thermal conductivity.

[0057] It should be noted that, in order to reduce the impact on the expansion of the stent body 1, the input line 51 and the output line 52 are both reserved with a free section of at least 30 mm, and after expansion, the input line 51 and the output line 52 still retain a partial bend.

[0058] Before use, the stent body 1, hot melt coating 2, drug layer 3, and coating layer 4 are pressed together in the microcatheter. After they are in place, the microcatheter is withdrawn, and the stent body 1 expands radially, driving the hot melt coating 2, drug layer 3, and coating layer 4 to expand. The stent body 1 is attached to the inner wall of the blood vessel, and the drug layer 3 is aligned with the lesion after expansion. At this time, the stent body 1 is powered on and heated, and the heat of the stent body 1 is transferred to the hot melt coating 2. The temperature is 40°C. After the hot melt coating 2 decomposes, the drug layer 3 is released and directly contacts the lesion to inhibit the proliferation of cells in the lesion. After that, the stent body 1 can be recovered, and the drug layer 3 remains attached to the lesion. The stent body 1 can be recovered and not left in the blood vessel. After completing its function, the stent body 1 of the drug stent will not stay in the body for a long time like a permanent implant, reducing the risk of long-term foreign body reaction and complications.

[0059] The present invention provides a hot-melt coating 2, a drug layer 3 and a covering layer 4. As the stent body 1 expands and adheres to the blood vessel wall, the hot-melt coating 2 is decomposed by heating, thereby releasing the drug to treat the lesion. After the drug is released, it can be recovered, and the stent body 1 will not remain in the body, thereby reducing the probability of thrombosis.

[0060] In a preferred embodiment of the present invention, the coating layer 4 is a PLG coating. The key advantage of the PLG coating is that it is biodegradable and can be degraded into lactic acid and glycolic acid after a period of time in the blood vessel, which have little impact on the physiological environment, thereby reducing the risk of thrombosis at the coating layer 4.

[0061] In a preferred embodiment of the present invention, the drug layer 3 is protruded away from the stent body 1. The purpose of the protruding drug layer 3 is to allow the drug to better contact the lesion after the hot-melt coating 2 is dissolved, thereby increasing the contact area.

[0062] In a preferred embodiment of the present invention, the heating assembly includes an input line 51 connected to the proximal end of the stent body 1, the part of the input line 51 located outside the body is connected to a power source, and the distal end of the stent body 1 is connected to an output line 52, and the stent body 1 heats itself by being powered on;

[0063] In a preferred embodiment of the present invention, a sheath tube 6 with two unconnected cavities is further included, and the input line 51 and the output line 52 are respectively located in one cavity. By providing two unconnected cavities, the input line 51 and the output line 52 are separated, reducing the possibility of short circuit. The sheath tube 6 is connected to the proximal end of the stent body 1. After the drug layer 3 is released, the stent body 1 can be recovered by pulling back the sheath tube 6.

[0064] In a preferred embodiment of the present invention, the hot melt coating 2 is made of a thermoplastic resin, including but not limited to polybutadiene. When heated to 40°C, the decomposition is accelerated. Thermoplastic resin has a certain tear resistance. When subjected to tearing force, the thermoplastic resin can disperse the stress by stretching and sliding itself, thereby avoiding rapid tearing of the hot melt coating 2.

[0065] In a preferred embodiment of the present invention, the drug layer 3 is any one or more of rapamycin, a structural derivative of rapamycin, paclitaxel, and a structural derivative of paclitaxel. The structural derivative of rapamycin includes but is not limited to everolimus and zotarolimus. Rapamycin and the structural derivative of rapamycin can inhibit the proliferation of vascular smooth muscle cells and reduce the excessive proliferation of the vascular endothelium after surgery when preventing restenosis.

[0066] The structural derivatives of paclitaxel include but are not limited to docetaxel and cabazitaxel. Paclitaxel and its structural derivatives can also reduce the excessive proliferation of the vascular endothelium after surgery by inhibiting the proliferation of vascular smooth muscle cells.

[0067] In a preferred embodiment of the present invention, a plurality of developing points 7 are arranged on the support body 1, and the developing points 7 are arranged at the connection between the support body 1 and the hot-melt coating 2. The developing points 7 are fixed on the support body 1 by bonding.

[0068] The hot-melt drug-releasing stent of the present invention is described in detail below through specific embodiments.

[0069] Example 1

[0070] This embodiment provides a hot melt release drug stent, referring to Figure 1 , Figure 2 and Figure 3 , including a stent body 1, which is woven from nickel-titanium alloy wires in a grid shape and can expand radially after release.

[0071] The stent body 1 is bonded with a hot melt coating 2, which is a film made of polybutadiene and has certain elasticity and flexibility. During the expansion of the stent body 1, the hot melt coating 2 can expand with the stent body 1 and maintain a bonding relationship with the stent body 1. The doctor can adjust the position of the stent body 1 by observing the position of the stent body 1 through the developing device, thereby controlling the position of the hot melt coating 2. It should be noted that polybutadiene will decompose when heated to 40°C, allowing the drug in the drug layer 3 to be released.

[0072] The drug layer 3 is an anti-proliferative drug, such as one or more of paclitaxel and rapamycin. One end of the drug layer 3 close to the hot-melt coating 2 is adhered to the hot-melt coating 2. After the hot-melt coating 2 is decomposed, the drug in the drug layer 3 is released and adheres to the vascular lesion, thereby inhibiting the proliferation of vascular smooth muscle cells and reducing the excessive proliferation of the vascular endothelium after surgery.

[0073] The coating layer 4 is a biodegradable film bonded to the hot-melt coating 2. The coating layer 4 and the hot-melt coating 2 form a cavity for accommodating the drug, which is used to wrap the drug layer 3 to prevent the loss of the drug layer 3 during transportation. The coating layer 4 is preferably a PLG coating. In the in vivo environment, the PLG coating is biodegradable and will gradually degrade into lactic acid and glycolic acid. These small molecule products are common substances in the human body's metabolic process and can be further decomposed and excreted from the body through metabolic pathways.

[0074] Reference Figures 1 to 5 The heating component includes an input line 51 connected to the proximal end of the stent body 1. The part of the input line 51 outside the body is connected to a power source. The distal end of the stent body 1 is connected to an output line 52. The stent body 1 is energized through a loop formed by the input line 51 and the output line 52 to heat the stent body 1. The stent body 1 has a certain thermal conductivity. A resistor block 53 located at the hot-melt coating 2 is welded on the stent body 1. The resistor block 53 is made of a material with a high resistivity, preferably copper. The resistor block 53 is embedded in the hot-melt coating 2 to increase the contact area. After conduction, the copper has a high resistance, which allows the resistor block 53 to accumulate heat and conduct the heat to the hot-melt coating 2, causing the hot-melt coating 2 to decompose and complete the release of the drug. The heating temperature of the stent body 1 is 40°C, which is not much different from the temperature inside the blood vessel, and has little impact on the environment inside the blood vessel.

[0075] Preferably, the input line 51 and the output line 52 have a 30 mm free section reserved in the clamped state. During the expansion of the stent body 1, the input line 51 and the output line 52 are straightened with the stent body 1, so that the input line 51 and the output line 52 can remain connected to the stent body 1 without restricting the expansion of the stent body 1.

[0076] In another embodiment of the present application, the heating temperature of the bracket body 1 is 41°C.

[0077] The hot-melt coating 2 is made of thermoplastic resin, preferably polybutadiene. When heated to 40°C, the hot-melt coating 2 decomposes rapidly.

[0078] Reference Figure 2 , Figure 3 and Figure 4Before use, the stent body 1, hot melt coating 2, drug layer 3, and coating layer 4 are pressed together in the microcatheter. After they are in place, the microcatheter is withdrawn, the stent body 1 expands radially, the hot melt coating 2, drug layer 3, and coating layer 4 expand with the stent body 1, the stent body 1 is attached to the inner wall of the blood vessel, and the drug layer 3 is aligned with the lesion after expansion. At this time, the stent body 1 is powered on and heated, and the stent body 1 accumulates heat and conducts it to the hot melt coating 2. The temperature is 40°C. After the hot melt coating 2 decomposes, the drug layer 3 is released and directly contacts the lesion to inhibit the proliferation of cells in the lesion. The sheath 6 is pulled to retract the stent body 1, while the drug layer 3 remains attached to the lesion. After completing the function, the stent body 1 of the drug stent will not remain in the body for a long time like a permanent implant, reducing the risk of long-term foreign body reaction and complications.

[0079] Preferably, a developing point 7 is bonded to the stent body 1. The developing point 7 can be made of platinum-iridium alloy and can display a light spot with a brightness different from other parts under the developing equipment to assist the doctor in determining the position of the stent body 1 and further reduce the difficulty of the surgical operation.

[0080] Example 2

[0081] This embodiment further describes how to recycle the bracket body 1 based on the embodiment 1. Figure 1 , Figure 3 , Figure 4 and Figure 5 A sheath 6 is welded to the proximal end of the stent body 1, and two cavities are set in the sheath 6 along the length direction, one cavity is for the input line 51 to pass through, and the other cavity is for the output line 52 to pass through. The two cavities are separated to prevent the input line 51 and the output line 52 from contacting and short-circuiting.

[0082] In summary, the present invention provides a hot-melt coating 2, a drug layer 3 and a covering layer 4. The drug layer 3 adheres to the lesion of the blood vessel after the stent body 1 expands. After adhering to the blood vessel wall, the stent body 1 is energized, and the resistor block 53 generates heat to decompose the hot-melt coating 2, thereby releasing the drug to treat the lesion. After the drug is released, it can be recovered, so that the stent body 1 does not remain in the body, reducing the probability of thrombosis.

[0083] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A hot-melt drug-releasing stent, characterized in that: It comprises a bracket body (1); A hot-melt coating (2) is provided on the support body (1); A drug layer (3) is disposed on the hot-melt coating (2); A coating layer (4) is disposed on the hot-melt coating (2) and covers the drug layer (3); The stent body (1) is connected to a heating assembly, the heating assembly comprises an input line (51) connected to the proximal end of the stent body (1), and the distal end of the stent body (1) is connected to an output line (52); The stent body (1) is provided with a resistor block (53) located at the hot-melt coating (2). When the resistor block (53) is energized, it generates heat and heats the hot-melt coating (2), causing the hot-melt coating (2) to decompose and release drugs.

2. The hot melt drug release stent according to claim 1, characterized in that: The coating layer (4) is a PLG coating.

3. The hot melt drug release stent according to claim 1, characterized in that: The drug layer (3) is arranged to protrude in a direction away from the stent body (1).

4. The hot-melt drug-releasing stent according to claim 1, characterized in that: The resistor block (53) is protrudingly arranged and embedded in the hot-melt coating (2).

5. The hot-melt drug-releasing stent according to claim 4, characterized in that: The stent body (1) is provided with a separation layer (11) located between the resistance block (53) and the hot-melt coating (2); the separation layer (11) is a thin film with good biocompatibility.

6. The hot-melt drug-releasing stent according to claim 1, characterized in that: It also includes a sheath tube (6) with two cavities that are not connected to each other, the input line (51) and the output line (52) are respectively located in one of the cavities, and the sheath tube (6) is connected to the proximal end of the stent body (1).

7. The hot-melt drug-releasing stent according to claim 6, characterized in that: The hot melt coating (2) is made of a thermoplastic resin, and the thermoplastic resin includes but is not limited to polybutadiene.

8. The hot-melt drug-releasing stent according to claim 4, characterized in that: The heating temperature of the support body (1) is 40°C-41°C.

9. The hot melt drug release stent according to any one of claims 1 to 8, characterized in that: The drug layer (3) is any one or more of rapamycin, its structural derivatives, paclitaxel, and its structural derivatives.

10. The hot-melt drug-releasing stent according to any one of claims 1 to 8, characterized in that: A plurality of developing points (7) are arranged on the support body (1), and a developing point (7) is also arranged at the connection between the support body (1) and the hot-melt coating (2).

Images